MicroRNAs: A Potential New Frontier for Medicine
Noted experts explore this topic in the April issue of Translational Research
New York, NY, March 23, 2011 – Since their discovery in the 1990s, microRNAs have proven to play a complex role in normal and abnormal functioning of many organ systems. In the April issue of Translational Research, entitled “MicroRNAs: A Potential New Frontier for Medicine,” an international group of medical experts explores several themes related to our current understanding of microRNAs and the role they may play in the future of medicine.
A commentary by Monty Montano, Department of Medicine, Boston University, provides a general introduction to this single-topic issue. He states, "In the coming years, there is much to be learned about adaptive (and maladaptive) states by examining how the expression of miRNAs is influenced by the genetic architecture of miR genes, clusters, and mirtrons, as well as miRNA polymorphism and polymorphism in their mRNA targets…Current efforts to leverage knowledge of this regulatory system to diagnose, track, and attenuate disease progression represent a major new research opportunity and challenge in this rapidly growing area of translational medicine."
microRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases
Rujuan Dai, and S. Ansar Ahmed
The authors review in great detail the functions of microRNAs in autoimmune diseases, inflammation processes, and immune system regulation.
Integrating microRNAs into a system biology approach to acute lung injury
Tong Zhou, Joe G.N. Garcia and Wei Zhang
The authors explore the possible role of microRNAs in inflammatory lung diseases and integration into a comprehensive disease model for acute lung injury.
MicroRNAs in idiopathic pulmonary fibrosis
Kusum V. Pandit, Jadranka Milosevic and Naftali Kaminski
The authors summarize current knowledge on the role of microRNAs in idiopathic lung fibrosis (IPF), highlighting how differentially expressed microRNAs in IPF will have a significant impact on our understanding of the disease.
Involvement of microRNAs in lung cancer biology and therapy
Xi Liu, Lorenzo F. Sempere, Yongli Guo, Murray Korc, Sakari Kauppinen, Sarah J. Freemantle and Ethan Dmitrovsky
The authors review how microRNAs can accelerate or suppress lung cancers and how this knowledge might serve as a basis for developing diagnostic markers or anti-cancer therapeutic agents.
MicroRNA biomarkers in lung cancer: MiRacle or quagMiRe?
Sai Yendamuri and Robert Kratzke
The authors explore some of the difficulties facing the development of microRNAs as biomarkers for lung disease, as well as some promising areas of research.
MicroRNAs as therapeutic targets in cancer
S. Patrick Nana-Sinkam and Carlo M. Croce
The authors review the challenges of translating current knowledge on microRNAs into effective clinical therapies for many cancers or as adjuvants for enhancing chemosensitivity to traditional therapies.
MicroRNAs in cardiac disease
Gerald W. Dorn II
The author examines the use of microRNAs as both biomarkers of cardiac diseases and as potential targets for therapies.
MicroRNAs in kidney function and disease
Sanjeev Akkina and Bryan N. Becker
The authors review the role of microRNAs in understanding the pathophysiology of kidney disease and potential therapeutic uses.
microRNAs and liver disease
Thomas A. Kerr, Kevin M. Korenblat and Nicholas O. Davidson
The authors review developments in microRNA research in the areas of pathogenesis of nonalcoholic fatty liver disease (NAFLD), viral hepatitis (C and B), and hepatocellular carcinoma (HCC), as well as the role of miRNAs as biomarkers of liver injury and HCC.
Diabetes mellitus, a microRNA-related disease?
Claudiane Guay, Elodie Roggli, Valeria Nesca, Cécile Jacovetti and Romano Regazzi
The authors review recent studies on the role of microRNAs in the pathogenesis of diabetes, including the role of several microRNAs in pancreatic beta cells and insulin-target tissues.
These articles appear in Translational Research, The Journal of Laboratory and Clinical Medicine, Volume 157, Issue 4 (April 2011) entitled “MicroRNAs: A Potential New Frontier for Medicine,” published by Elsevier.
# # #
Full text of the articles is available to journalists upon request. Contact Pat Hogan at 212-633-3944, firstname.lastname@example.org to obtain copies or to schedule an interview with Editor-in-Chief Jeffrey Laurence, MD.
About Translational Research ( www.translationalres.com)
The official journal of the Central Society for Clinical Research ( www.cscr.com), Translational Research delivers original investigations in the broad fields of laboratory, clinical, and public health research. Interdisciplinary and cross-disciplinary in scope, it keeps readers up-to-date on significant biomedical research from all subspecialties of medicine. Aiming to expedite the translation of scientific discovery into new or improved standards of care, it promotes a wide-ranging exchange between basic, preclinical, clinical, epidemiologic, and health outcomes research. It encourages submission of studies describing preclinical research with potential for application to human disease, and studies describing research obtained from preliminary human experimentation with potential to refine the understanding of biological principles underpinning human disease. Also encouraged are studies describing public health research with potential for application to the clinic, disease prevention, or healthcare policy.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media Contact